A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies

Investigational New Drugs - 2023
Danny N. Khalil1,2,3, Isabel Prieto González-Albo4, Lee Rosen5, Tom Lillie4, Andrea Stacey4, Lola Parfitt4, Gerald A. Soff6
1Parker Institute for Cancer Immunotherapy, New York, USA
2Weill Cornell Medicine, New York, USA
3Memorial Sloan Kettering Cancer Center, New York, USA
4Akamis Bio Ltd, Abingdon, Oxford, UK
5UCLA Medical Center, Los Angeles, USA
6University of Miami Health System/Sylvester Comprehensive Cancer Center, Miami, USA

Tóm tắt

Tumor-selective viruses are a novel therapeutic approach for treating cancer. Tumor-Specific Immuno Gene Therapy (T-SIGn) vectors are tumor-selective adenoviral vectors designed to express immunomodulatory transgenes. Prolonged activated partial thromboplastin time (aPTT), associated with the presence of antiphospholipid antibodies (aPL), has been observed in patients with viral infections, and following administration of adenovirus-based medicines. aPL may be detected as lupus anticoagulant (LA), anti-cardiolipin (aCL) and/or anti-beta 2 glycoprotein antibodies (aβ2GPI). No subtype alone is definitive for development of clinical sequalae, however, patients who are ‘triple positive’ have a greater thrombotic risk. Additionally, isolated aCL and aβ2GPI IgM do not appear to add value in thrombotic association to aPL positivity, rather IgG subtypes must also be present to confer an increased risk. Here we report induction of prolonged aPTT and aPL in patients from eight Phase 1 studies who were treated with adenoviral vectors (n = 204). Prolonged aPTT (≥ Grade 2) was observed in 42% of patients, with a peak at 2–3 weeks post-treatment and resolution within ~ 2 months. Among patients with aPTT prolongation, LA, but not aCL IgG nor aβ2GPI IgG, was observed. The transience of the prolongation and discordance between positive LA and negative aCL/aβ2GPI IgG assays is not typical of a prothrombotic state. Among the patients with prolonged aPTT there was no evidence of an increased rate of thrombosis. These findings elucidate the relationship between viral exposure and aPL in the context of clinical trials. They suggest a framework in which hematologic changes can be monitored in patients receiving similar treatments. Clinical trial registration: NCT02028442, NCT02636036, NCT02028117, NCT03852511, NCT04053283, NCT05165433, NCT04830592, NCT05043714.

Từ khóa


Tài liệu tham khảo

Machiels JP, Salazar R, Rottey S, Duran I, Dirix L, Geboes K et al (2019) A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). J Immunother Cancer 7(1):20

Moreno V, Barretina-Ginesta M-P, García-Donas J, Jayson GC, Roxburgh P, Vázquez RM et al (2021) Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. J Immunother Cancer 9(12):e003645

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM et al (2017) Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer 5(1):71

Garcia D, Erkan D (2018) Diagnosis and management of the Antiphospholipid Syndrome. N Engl J Med 378(21):2010–2021

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, CERVERA R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306

Devreese KM (2014) Antiphospholipid antibody testing and standardization. Int J Lab Hematol 36(3):352–363

Chayoua W, Kelchtermans H, Moore GW, Musiał J, Wahl D, de Laat B et al (2018) Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays. J Thromb Haemost 16(10):2016–2023

Chayoua W, Kelchtermans H, Gris JC, Moore GW, Musiał J, Wahl D et al (2020) The (non-)sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost 18(1):169–179

Vandevelde A, Chayoua W, de Laat B, Gris J-C, Moore GW, Musiał J et al (2022) Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies. J Thromb Haemost 20(2):508–524

Asherson RA, Cervera R (2003) Antiphospholipid antibodies and infections. Ann Rheum Dis 62(5):388–393

Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME (2018) Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus 27(4):572–583

Malaeb BS, Gardner TA, Margulis V, Yang L, Gillenwater JY, Chung LWK et al (2005) Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants. Urology 66(4):830–834

Crank MC, Wilson EM, Novik L, Enama ME, Hendel CS, Gu W et al (2016) Safety and Immunogenicity of a rAd35-EnvA prototype HIV-1 vaccine in combination with rAd5-EnvA in healthy adults (VRC 012). PLoS ONE 11(11):e0166393

Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G et al (2010) A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29(2):304–313

Sheets RL, Stein J, Bailer RT, Koup RA, Andrews C, Nason M et al (2008) Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer’s construct, or gene inserts. J Immunotoxicol 5(3):315–335

Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F et al (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137(14):1959–1969

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723

Fakih M, Wang D, Harb W, Rosen L, Mahadevan D, Berlin J et al (2019) A phase I multicenter study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: an analysis of the metastatic colorectal cancer patients in the dose escalation phase. Ann Oncol 30(Suppl 5):V198–V252

Krige D, Fakih M, Rosen L, Wang D, Harb W, Babiker H et al (2021) 342 Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study. J Immunother Cancer 9(Suppl 2):A368–A9

Naing A, Rosen L, Camidge RD, Khalil D, Davies J, Miles D et al (2021) 1011P FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results. Ann Oncol 32:S853–S4

Lillie T, O’Hara M, Ottensmeier C, Parkes E, Rosen L, Krige D et al (2022) Abstract CT213: a multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY). Cancer Res 82(12Supplement):CT213–CT

Simon G, Subbiah V, Rosen L, Lenz H-J, Park H, Patel M et al (2022) 762 First-in-human phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR). J Immunother Cancer 10(Suppl 2):A793–A

Ottensmeier C, Evans M, King E, Karydis I, Lillie T, Krige D et al (2021) 437 A multicentre phase 1b study of NG-641, a novel transgene-armed and tumour-selective adenoviral vector, and pembrolizumab as neoadjuvant treatment for squamous cell carcinoma of the head and neck. J Immunother Cancer 9(Suppl 2):A467–A

Lillie T, Parkes E, Ottensmeier C, Krige D, Ravanfar B, Evilevitch V et al (2022) Abstract CT214: a multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA). Cancer Res 82(12Supplement):CT214–CT

Wiwanitkit V (2004) Activated partial Thromboplastin Time abnormality in patients with Cholangiocarcinoma. Clin Appl Thromb Hemost 10(1):69–71

Liu J, Li F, Shu K, Chen T, Wang X, Xie Y et al (2018) The analysis of false prolongation of the activated partial thromboplastin time (activator: silica): interference of C-reactive protein. J Clin Lab Anal 32(8):e22571

Ay C, Pabinger I, Cohen AT (2017) Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 117(2):219–230

Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, Suarez-Almazor ME (2016) Systematic review of case reports of antiphospholipid syndrome following infection. Lupus 25(14):1520–1531

Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni P-L (2006) Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 65(1):2–6

Gharavi AE, Pierangeli SS, Harris EN (2001) Origin of antiphospholipid antibodies. Rheum Dis Clin North Am 27(3):551–563

de Laat B, Mertens K, de Groot PG (2008) Mechanisms of Disease: antiphospholipid antibodies—from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol 4(4):192–199

Thông tin
Thông tin xuất bản

Investigational New Drugs

Thông tin tác giả